Intercept Pharma cools off after presentation

Intercept Pharmaceuticals (ICPT +1.9%) gives up early gains as the company presents at the JPMorgan Healthcare Conference.

Investor expectations might have been somewhat unrealistic going into the event.

Of note, reports suggest the company is in ongoing talks with the FDA regarding accelerated approval of OCA in PBC and intends to file based on Phase 3 data from POISE.

POISE results expected in Q2.

See also: 2014 clinical and regulatory milestones slide here.

From other sites
Comments (2)
  • UESnick
    , contributor
    Comments (22) | Send Message
    No FDA Approval from the FDA for OCA in PBC ???? Sounds like the cart is in front of the horse by miles here. The market has very unrealistic expectations here.
    15 Jan 2014, 11:07 AM Reply Like
  • TruffelPig
    , contributor
    Comments (4208) | Send Message
    10% up. Yeah, that is pretty damned cool ;P
    15 Jan 2014, 06:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs